 <h1>Risankizumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to risankizumab: subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, risankizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking risankizumab:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>chest pain</li>
<li>chills</li>
<li>confusion</li>
<li>cough</li>
<li>difficulty in breathing</li>
<li>dizziness</li>
<li>ear congestion</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>headache</li>
<li>increase in bone pain</li>
<li>itching, pain, redness, swelling, tenderness, or warmth on the skin</li>
<li>lightheadedness</li>
<li>loss of voice</li>
<li>painful blisters on the trunk of the body</li>
<li>rapid, shallow breathing</li>
<li>runny or stuffy nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>tightness in the chest</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Itching of the genitals or other skin areas</li>
<li>scaling of the skin</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Burning, itching, and pain in hairy areas, pus at the root of the hair</li>
<li>hives or welts, itching, skin rash</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of risankizumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to risankizumab: subcutaneous kit</i></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Immunogenicity (24%), infections (e.g., cellulitis, osteomyelitis, sepsis, herpes zoster) (22%)</p>
<p><b>Common</b> (1% to 10%): Tinea infections (e.g., tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, tinea infection)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site reactions (e.g., bruising, erythema, extravasation, hematoma, hemorrhage, infection, inflammation, irritation, pain, pruritus, reaction, swelling, warmth)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory infections (e.g., respiratory tract infection [viral, bacterial, unspecified], sinusitis [including acute], rhinitis, nasopharyngitis, pharyngitis [including viral], tonsillitis) (13%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, asthenia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache (e.g., tension headache, sinus headache, cervicogenic headache)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Folliculitis, urticaria<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What are the new drugs for the treatment of plaque psoriasis?</li>
<li>Skyrizi vs Ilumya. What’s the difference?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about risankizumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: interleukin inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Risankizumab-rzaa Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Skyrizi</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Plaque Psoriasis</li>
<li>Psoriasis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to risankizumab: subcutaneous kit</i></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Immunogenicity (24%), infections (e.g., cellulitis, osteomyelitis, sepsis, herpes zoster) (22%)</p><p><b>Common</b> (1% to 10%): Tinea infections (e.g., tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, tinea infection)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site reactions (e.g., bruising, erythema, extravasation, hematoma, hemorrhage, infection, inflammation, irritation, pain, pruritus, reaction, swelling, warmth)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory infections (e.g., respiratory tract infection [viral, bacterial, unspecified], sinusitis [including acute], rhinitis, nasopharyngitis, pharyngitis [including viral], tonsillitis) (13%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, asthenia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache (e.g., tension headache, sinus headache, cervicogenic headache)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Folliculitis, urticaria<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, North Chicago, IL. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the new drugs for the treatment of plaque psoriasis?</li>
<li>Skyrizi vs Ilumya. What’s the difference?</li>
</ul><h2>More about risankizumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: interleukin inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Risankizumab-rzaa Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Plaque Psoriasis</li>
<li>Psoriasis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>